Monitoring Monoclonal Gammopathies
Slide Images
November 2009
This first slide illustrates some important concepts of plasma cell proliferative diseases. The 3 sections of this slide show a Wright-Giemsa-stained bone marrow with a large number of plasma cells, below that is an immunofluorescent stain for cytoplasmic Kappa light chains showing monoclonality of the plasma cells, and on the right of this slide is a bone scan showing bone lesions resulting from foci of proliferating plasma cells.
The concepts that I want to illustrate are first, the disease resides in the bone marrow and is not uniformly distributed throughout the body. That means that monitoring disease by directly quantitating plasma cells in bone marrow biopsies is problematic. Second, the immunofluorescent micrograph illustrates what plasma cells do best – they synthesize immunoglobulins. The secreted, monoclonal immunoglobulin serves as a tumor marker, which we can measure in the serum and/or urine, and which we use to monitor disease.
Slide Images |
Jump to section:
- Introduction
- Slide Images
- International Myeloma Working Group: Disease Monitoring
- Serum Protein Electrophoresis and Immunofixation Electrophoresis
- Serum and Urine Protein Electrophoresis and Immunofixation Electrophoresis
- Methods for Monitoring Monoclonal Gammopathies: 2005 IMWG
- Methods for Monitoring Monoclonal Gammopathies
- Small IgG kappa M-spike
- Large IgG kappa M-spike
- Relationship of Serum Agarose Electrophoresis M-spike and Ig Quantitation1
- Disease Monitoring
- Monoclonal Gammopathies: Primary Systemic Amyloidosis
- Free Light Chain: Antibody Specificity
- FLC κ/λ Ratio: Disease Sensitivity2
- Methods for Monitoring Monoclonal Gammopathies
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring3
- Response Criteria for FLC4,5
- Receiver Operator Curve (ROC): % FLC Reduction vs. Overall Hematologic Response6
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring
- References
- Questions?